Oral therapy for multiple sclerosis - Sea change or incremental step?

New England Journal of Medicine

Volumn 362, Issue 5, 2010, Pages 456-458

  Carroll, William M ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; GLATIRAMER; NATALIZUMAB;

ATRIOVENTRICULAR BLOCK; BASAL CELL CARCINOMA; BRADYCARDIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; DISEASE DURATION; DOWN REGULATION; DRUG EFFICACY; DRUG FORMULATION; EDITORIAL; EXPANDED DISABILITY STATUS SCALE; HUMAN; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

EID: 76149142826     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0912019     Document Type: Editorial

References (12)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
2. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.
3. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
4. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or in tramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
5. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60.
6. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the Evidence Trial. Neurology 2002;59:1496-506.
7. Achiron A, Fredrikson S. Lessons from randomised direct comparative trials. J Neurol Sci 2009;277:Suppl 1:S19-S24.
8. Iaffaldano P, D'Onghia M, Trojano M. Safety profile of Tysabri: international risk management plan. Neurol Sci 2009;30:Suppl 2:S159-S162.
9. Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother 2005;5:721-7.
10. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate - modifiers of lymphocyte migration. N Engl J Med 2006;355:1088-91.
11. The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
12. Goodin DS, Bates D. Treatment of early multiple sclerosis: value of treatment initiation after a first clinical episode. Mult Scler 2009;15:1175-82.